Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

WHO Director-General outlines vision for reform in World Health Assembly opening address

WHO Director-General Margaret Chan on Monday laid out her vision for reforming the international health agency in the opening address of the World Health Assembly in Geneva, saying she sees "a WHO that gives a bigger voice to the many partners working on health, but encourages them to speak with a coherent voice that responds, first and foremost, to the needs and priorities as defined by recipient countries," Intellectual Property Watch reports.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

World Health Assembly begins in Geneva

As the 64th World Health Assembly gets underway in Geneva, the body will consider "an array of subjects pertaining to reforms of the organisation and its financing, vaccines, fake medicines, and influenza pandemic preparedness, as well as communicable and non-communicable diseases," Intellectual Property Watch reports.

17 May 2011

Computationally designed antiviral proteins may fight against influenza

A research article May 12 in Science demonstrates the use of computational methods to design new antiviral proteins not found in nature, but capable of targeting specific surfaces of flu virus molecules.

16 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

Sinovac first quarter sales increase 5.3% to $4.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2011.

13 May 2011

Increase in public health spending linked with reduction of pandemic influenza mortality

Pandemic A (H1N1) 2009 mortality rates exhibited wide diversion between countries. Based on data from a total of 30 European countries, a study published in the journal PLoS ONE found that the greater the state financial "generosity" to health sector the lower the pandemic influenza mortality.

13 May 2011

Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

Aethlon Medical, Inc. announces that it has submitted a request to the U.S. Food and Drug Administration for a face-to-face meeting to discuss re-initiation of an Investigational Device Exemption (IDE) study of the Aethlon Hemopurifier in the United States.

10 May 2011

Novavax first quarter net loss decreases to $7.5 million

Novavax, Inc. today announced its financial results for the first quarter ended March 31, 2011.

9 May 2011

NBA Cares, SAHM and Tulsa Shock guard partner for teen vaccine awareness campaign

Tulsa Shock guard Andrea Riley and Basketball Hall of Famer Bob Lanier teamed up with NBA Cares and the Society for Adolescent Health and Medicine today to bring Vaccines for Teens to the Tulsa community.

5 May 2011

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Health. This approval marks a very important milestone, namely that all nine countries in the study have now given official government approval. Five of about 48 clinical centers for this global trial will be located in Poland.

5 May 2011

Pregnant women with H1N1 more likely to have low birth weight baby

In 2009, the United States was gripped by concern for a new winter threat: the H1N1 strain of influenza. According to research conducted through that winter, pregnant women were right to be concerned.

3 May 2011

HIV/AIDS research in Africa

Nowhere in the world has the AIDS/HIV pandemic cut a greater swath of devastation than in sub-Saharan Africa, where two-thirds of all people infected with the virus reside. As Barbara Smith, PhD, RN, FAAN, discovered firsthand, no segment of society there has been left unscathed.

30 Apr 2011

Healthcare advertising agencies earn Med Ad News recognition

UBM Canon has announced the winners of the 22nd annual Med Ad News Manny Awards 2011. The gala event, held at the Sheraton New York Hotel and Towers, culminated with the naming of AbelsonTaylor Inc. as Agency of the Year: Category I.

30 Apr 2011

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.

30 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

EPO grants patent to Microbix' VIRUSMAX vaccine enhancement technology

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies to enhance vaccine production yields, and other innovative biologics, announced today that the European Patent Office recently granted patent protection for the company's proprietary VIRUSMAX technology, which is designed to increase influenza vaccine yields and has demonstrated an average yield increase of at least two-fold over current vaccine production methods.

27 Apr 2011

New study sheds light on evolution of 2009 pandemic influenza A(H1N1) virus in Japan

Analysis of mutations of the 2009 pandemic influenza A(H1N1) virus by researchers at the RIKEN Omics Science Center (OSC) has revealed major genetic differences between the virus in its early phase of infection in Japan and in its peak phase. While yielding valuable clues on the genetic origins of drug resistance, the findings also pave the way toward the development of new diagnostic kits for detecting and preventing the spread of global pandemic diseases.

26 Apr 2011

FDA grants Cepheid marketing clearance for Xpert Flu diagnostic test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® Flu. The diagnostic test, which runs on Cepheid's GeneXpert® System, simultaneously detects and differentiates Influenza A, Influenza B, and the 2009 H1N1 influenza virus in about one hour.

26 Apr 2011

Congressman Holt congratulates Vaxinnate for BARDA award to develop next generation of flu vaccines

U.S. Congressman Rush Holt (R-12th) visited the headquarters of VaxInnate Corporation today, where he congratulated the biotechnology company on having received a U.S. government contract to fund development of the next generation of flu vaccines and called for more technology investments to improve the health of all Americans.

22 Apr 2011

Pandemic News and Research

Further Reading

WHO Director-General outlines vision for reform in World Health Assembly opening address

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

World Health Assembly begins in Geneva

Computationally designed antiviral proteins may fight against influenza

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

Sinovac first quarter sales increase 5.3% to $4.7 million

Increase in public health spending linked with reduction of pandemic influenza mortality

Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

Novavax first quarter net loss decreases to $7.5 million

NBA Cares, SAHM and Tulsa Shock guard partner for teen vaccine awareness campaign

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

Pregnant women with H1N1 more likely to have low birth weight baby

HIV/AIDS research in Africa

Healthcare advertising agencies earn Med Ad News recognition

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

EPO grants patent to Microbix' VIRUSMAX vaccine enhancement technology

New study sheds light on evolution of 2009 pandemic influenza A(H1N1) virus in Japan

FDA grants Cepheid marketing clearance for Xpert Flu diagnostic test

Congressman Holt congratulates Vaxinnate for BARDA award to develop next generation of flu vaccines

Best practices - optimize qPCR processes for pathogen detection eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News